உள் மருத்துவம்: திறந்த அணுகல்
திறந்த அணுகல்

சுருக்கம்

Screening for Cardiac Sarcoidosis with the MRI under Immunosuppressive Therapy

Theresa Reiter, Irmengard Perdijk, Pius Jung, Jürgen Wolf, Theo Pelzer and Wolfgang R. Bauer

The cardiac affection in systemic sarcoidosis often presents as functional impairment or rhythmic abnormalities and is of prognostic relevance. Due to the focal granulomatous changes, the detection of the sarcoid lesions can be challenging. Cardiac MRI allows for a unique non-invasive presentation of the cardiac structure, and detects these typical changes even in up to 30% of asymptomatic patients. Treatment options include immunosuppressive therapies such as systemic corticosteroids that suppress the inflammatory processes. In an unfiltered group of sarcoidosis patients, however, many of the patients will be or already had been on immunosuppressive therapy, often due to an extra-cardiac affection. The presented study examines the influence of the immunosuppressive therapy on the findings of the initial screening MRI. All included patients have been seen at the University of Wuerzburg’s Centre for Rare Diseases (ZESE). In the context of the diagnostic workup, a cardiac MRI (1.5 or 3.0 T) was performed including morphologic, functional, and contrast enhanced imaging as well as edema imaging. All data were analyzed retrospectively. 171 patients with an eventually biopsy proven systemic sarcoidosis were included in the analysis. At the time of the MRI imaging procedure 58% of these patients had never had an immunosuppressive therapy, 22% had had already received an immunosuppressive therapy and 19% were currently under treatment. 21% of all patients showed positive MRI findings (11% without therapy, 9.4% with a prior or ongoing therapy). Between these groups, statistically no differences in the detection of late enhancement, edema and wall motion abnormalities were detected. The data of the analyzed population showed that the MRI is a valuable screening tool for both acute and past myocardial affection in the management of patients with sarcoidosis regardless of their current or prior treatment.